Liraglutide (Victoza): what the drug actually does vs. the hype

What did @dr.mikediabetes actually say?

Honestly, this is one of the harder transcripts to work with. The video is a bilingual response to a viewer question about liraglutide (Victoza), but the transcript is largely incoherent, a mix of garbled English and fragmented Spanish that doesn't form clear medical claims. The creator does gesture toward liraglutide's role in "controlling peso" (weight) and references something called "CORTA" as a significant benefit. They also include a brief disclaimer telling viewers to consult their doctor before acting on anything shared.

The clearest takeaway from what was actually said is that liraglutide has weight-related benefits, and that viewers should not self-medicate. Beyond that, the transcript does not deliver structured medical information about how liraglutide works, what it's approved for, its side effect profile, or how it compares to newer GLP-1 agents like semaglutide. The video's caption promises to explain "what is Victoza liraglutide for" but the content doesn't deliver that explanation in any coherent way.

Does the science back this up?

On the narrow point that liraglutide helps control weight, yes, the evidence is solid. But the transcript is too vague to fact-check most of it rigorously.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in two formulations: Victoza (1.2 mg or 1.8 mg daily) for type 2 diabetes management, and Saxenda (3.0 mg daily) for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed that liraglutide 3.0 mg produced a mean weight loss of 8.4 kg versus 2.8 kg for placebo over 56 weeks. For diabetes, the LEADER trial (Marso et al., 2016, NEJM) demonstrated cardiovascular mortality reduction in high-risk type 2 diabetes patients. These are real, meaningful benefits. The problem is the video doesn't actually explain any of them clearly.

What did they get wrong (or right)?

What they got right: there is a disclaimer. The creator does say in fragmented Spanish to consult your doctor before applying any advice shared in the video. That's the bare minimum, and credit where it's due, it's there.

What's wrong or missing is more significant. The term "CORTA" as described is unrecognizable as a clinical term related to liraglutide's mechanism or benefits. Liraglutide works by mimicking endogenous GLP-1, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and reducing appetite via hypothalamic pathways (Drucker, 2018, Cell Metabolism). None of this is explained. The claim that something is "stronger than the body" has no clinical meaning. And describing liraglutide's benefits as "the most impressive in the world" without context around its known limitations, including nausea in roughly 40% of patients and the fact that it has largely been displaced by more effective agents like semaglutide, is an overstatement that misleads viewers.

What should you actually know?

Liraglutide is a legitimate, well-studied medication with real clinical uses. It is not a cure for diabetes or obesity. It is a management tool that works best alongside diet changes and regular follow-up with a prescribing clinician.

• Victoza (liraglutide 1.2-1.8 mg) is FDA-approved for type 2 diabetes and reduces cardiovascular risk in high-risk patients (LEADER trial, Marso et al., 2016, NEJM).
• Saxenda (liraglutide 3.0 mg) is FDA-approved for weight management, not the same indication as Victoza despite being the same molecule at a different dose.
• Common side effects include nausea, vomiting, and diarrhea, particularly during dose escalation. These are not minor inconveniences for many patients.
• Liraglutide has been largely superseded in weight loss efficacy by semaglutide (Wegovy) and tirzepatide (Zepbound), both of which show greater average weight reduction in head-to-head or comparative trials (Wilding et al., 2021, NEJM; Jastreboff et al., 2022, NEJM).
• Contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. These are serious and not mentioned in the video.

If you're considering liraglutide, the conversation starts with your prescriber, not a TikTok comment thread, no matter how well-intentioned the creator is.